Nuevas vías de administración de Trastuzumab MIQUEL ÀNGEL SEGUÍ PALMER
|
|
- Job Bryan Sullivan
- 6 years ago
- Views:
Transcription
1 Nuevas vías de administración de Trastuzumab MIQUEL ÀNGEL SEGUÍ PALMER
2 Trastuzumab, a humanized monoclonal antibody against the extracellular domain of the HER2 receptor, is the standard-of-care treatment for patients with early and advanced HER-2 positive breast cancer Rituximab and trastuzumab were the first monoclonal antibodies (mabs) approved for the treatment of cancer. In oncology, mabs are typically administered by intravenous (IV) infusion; however, this administration route faces some challenges
3 Challenges of Intravenous administration of mabs The need for trained personnel, dedicated infusion facilities, dose calculation, aseptic preparation of required infusion volumes, and extended post-infusion observation. Long infusion times and slow workflow for medical staff. Potential difficulties with IV catheter placements. Risk of infusion-related reactions and complications (e.g. relevant thromboembolic events, infections), leading to hospitalisation and additional costs. Costs associated with the placement of permanent IV lines.
4 Revenues of IV versus SC-administered anti-tnf-alpha treatments ( )
5 Subcutaneous (SC) administration can potentially overcome many of these challenges. Although administration-associated reactions (AARs) may occur with SC administration, they are likely to be less severe than IV-associated infusion-related reactions, given the more gradual absorption of the SC formulation. SC formulations may be more convenient for patients, offering potential improvements in quality of life and treatment adherence. In oncology, SC administration of mabs has been shown to reduce administration times and health-care costs relative to IV infusion.
6 However, the biggest challenge with SC formulations has been the ability to deliver the required volume of drug to patients. The extracellular matrix, which maintains tissue architecture and controls diffusion/molecule flow, limits drug volumes to 1 2 ml, with volumes >2ml causing tissue distortion and pain. The extracellular matrix is composed of a structural network of fibrous proteins (collagen and elastin)embedded within a hydrated viscoelastic gel, composed of glycosaminoglycans that are complex linear polysaccharides characterized by repeating disaccharide structures of an N-substituted hexosamine and an uronic acid, including hyaluronan (hyaluronic acid9, chondroitin sulfate, dermatan sulfate, heparin sulfate, heparin and keratin sulfate.
7 Development of a SC Formulation of Trastuzumab These hurdles have been overcome by concentrating IV formulations 12-fold and adding recombinant human hyaluronidase (rhuph20). By hydrolysing hyaluronan, rhuph20 reversibly opens the interstitial space in SC tissue and allows the installation of >2 3 ml.
8 Administration site before and immediately after infusion without and with rhuph20
9 Clinical trials of subcutaneous trastuzumab in patients with HER2+ early stage breast cancer
10 Comparison of SC and IV Administration of Trastuzumab. Phase I/Ib Trial A subcutaneous trastuzumab dose of 8 mg/kg was found to result in exposure comparable with the intravenous trastuzumab dose of 6 mg/kg. The subcutaneous formulation was well tolerated. Wynne C et al. J Clin Pharmacol. 2013;53(2):
11 Development of a Fixed-Dose Subcutaneous Formulation of Trastuzumab The fixed dose of subcutaneous trastuzumab given every 3 weeks was determined by pharmacokinetic modelling of data from the phase I. 600-mg trastuzumab s.c. dose, administered thriceweekly (Q3W) without a loading dose, would provide C trough (predose Cycle 8) and area under the time concentration curve (AUC 0 21 days, Cycle 7) at least as high as Q3W i.v. administration. Hourcade-Potelleret F et al. CPT Pharmacometrics Syst. Pharmacol. (2014) 3, e87
12 HannaH Trial Fixed Dose for Trastuzumab SC Comparable Efficacy Expected Based on PK Profiles
13 HannaH Trial Randomized Open-Label Phase III Non-Inferiority Study to Compare the PK, Efficacy and Safety of Trastuzumab SC and IV in HER2-Positive EBC
14 Baseline patient demographic and tumour characteristics Ismael G, et al. Lancet Oncol. 2012;13(9);
15 HannaH Trial: Efficacy Results Ismael G, et al. Lancet Oncol. 2012;13(9);
16 HannaH Trial: Safety and Tolerability Ismael G, et al. Lancet Oncol. 2012;13(9);
17 HannaH Trial: Anti-Drug Antibodies (ADAs) Ismael G, et al. Lancet Oncol. 2012;13(9);
18 HannaH Trial Demonstrated the noninferiority of the fixed-dose SC trastuzumab formulation vs the IV formulation by meeting the co-primary endpoints of noninferior serum trough concentration and pathologic complete response (pcr) with neo)adjuvant SC trastuzumab via manual injection compared to IV The overall safety profile of the fixed-dose SC trastuzumab formulation was comparable to that of IV trastuzumab, and consistent with the known safety profile of trastuzumab in early breast cancer
19 PrefHer Trial To investigate benefits of the trastuzumab SC formulation, the international, multicenter, openlabel, randomized, two-cohort, two-arm PrefHer study was designed to assess patients preferences for trastuzumab SC or IV in the adjuvant breast cancer setting.
20 PrefHer Trial 1. Pivot X, et al. Lancet Oncol. 2013;14(10): Pivot X, et al. Cancer Res. 2013;73(24 Suppl): Abstract P
21 Cohort 1: Trastuzumab SC administered via SID Patient Preferences High preference for trastuzumab SC was maintained, irrespective of whether patients were de novo or non-de novo trastuzumab IV prior to study enrolment. Pivot X, et al. Lancet Oncol. 2013;14(10):962-70
22 Cohort 1: Trastuzumab SC administered via SID Primary Reasons for Patients Preferences Pivot X, et al. Lancet Oncol. 2013;14(10):962-70
23 Cohort 1: Trastuzumab SC administered via SID Strength of Patients Preferences Pivot X, et al. Lancet Oncol. 2013;14(10):962-70
24 Cohort 1: Trastuzumab SC administered via SID Healthcare Professional (HCP) Satisfaction Pivot X, et al. Lancet Oncol. 2013;14(10):962-70
25 Cohort 2: Trastuzumab SC administered via SC hand-held syringe Patients Preferences Pivot X, et al. Cancer Res. 2013;73(24 Suppl): Abstract P
26 Cohort 2: Trastuzumab SC administered via SC hand-held syringe Strength of Patients Preferences Pivot X, et al. Cancer Res. 2013;73(24 Suppl): Abstract P
27 Cohort 2: Trastuzumab SC administered via SC hand-held syringe Healthcare Professional (HCP) Satisfaction Pivot X, et al. Cancer Res. 2013;73(24 Suppl): Abstract P
28 Patients in the PrefHer study had a very strong preference for SC over IV trastuzumab, mainly because it saved them time and caused them less pain/discomfort/side effects than IV administration. Confirmed advantages of SC trastuzumab administration include: - Improved patient convenience - Reduced use of hospital resources and the time of healthcare professionals There was a high level of healthcare professional satisfaction with SC trastuzumab. The overall safety profile of 4 cycles of trastuzumab SC and 4 cycles of trastuzumab IV observed during the crossover period in the PrefHer study was consistent with the known safety profile of trastuzumabin early breast cancer. Safety data did not raise any safety concerns thus far.
29 SafeHer Trial Design
30 Patient time associated with IV and SC trastuzumab formulations Lopez-Vivanco G et al. 19th Congress of the European Association of Hospital Pharmacists March 2014,
31 Conclusions For patients receiving treatment over prolonged periods, SC administration offers significant benefits over IV administration and is considered convenient. SC formulations of trastuzumab can potentially improve convenience and quality of life for patients and provide cost savings to health-care systems. Patient preference and safety results from PrefHer, combined with efficacy, pharmacokinetic, and safety results from HannaH, suggest that a fixed dose of 600 mg trastuzumab SC every 3 weeks, for about 5 min, is a validated, well tolerated, and preferred option for the treatment of HER2-positive breast cancer
32
33
Clinical and statistical considerations of bridging approaches to alternative dosing regimen or formulations
Clinical and statistical considerations of bridging approaches to alternative dosing regimen or formulations Dominik Heinzmann, PhD Global Development Team Leader Biostatistics Manager F. Hoffmann-La Roche,
More informationPROF. DR. MED. C. JACKISCH
PROF. DR. MED. C. JACKISCH Introduction of subcutaneous formulation: optimization of medcial unmet needs and hospital adminstration challenges from a physicians perspective Department of Obstetrics & Gynecology
More informationSubcutaneous (SQ) Hydration Augmented by Hyaluronidase
Subcutaneous (SQ) Hydration Augmented by Hyaluronidase Reassess @ 60min Repeat Gorelick scale, VS PO challenge Repeat bolus? Dehydration Assessment with Gorelick Scale (see attached) > 4 wks of age Failed
More informationHalozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. The Next Chapter Begins: Creating Value Through Growth Jefferies 2014 Global Health Care Conference June 2014 Helen Torley, M.B. Ch. B., M.R.C.P. President and Chief Executive
More informationPresent and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer
Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer Christoph C. Zielinski Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center,
More information79956F Kitano et al_bi754091bi TiP_JSMO 2018 (NB).pdf 1 13/07/ :55:06 C M Y CM MY CY CMY K
79956F Kitano et al_bi754091bi754111 TiP_JSMO 2018 (NB).pdf 1 13/07/2018 13:55:06 C M Y CM MY CY CMY K Phase 1 trial of an anti-pd-1 mab BI 754091 ± an anti-lag-3 mab BI 754111 in Asian patients with advanced
More informationLCA Breast Pathway 4 th Clinical Forum Systemic Treatments of Breast Cancer 3 rd December 2013
LCA Breast Pathway 4 th Clinical Forum Systemic Treatments of Breast Cancer 3 rd December 2013 Welcome and LCA Breast Pathway Update Dr Will Teh, Chair - LCA Breast Pathway Group Thank you for coming today
More informationIMMUNOGLOBULIN REPLACEMENT THERAPY: ONE SIZE DOESN T FIT ALL
PRIMARY IMMUNODEFICIENCIES IMMUNOGLOBULINS: ONE SIZE DOESN T FIT ALL IMMUNOGLOBULIN REPLACEMENT THERAPY: ONE SIZE DOESN T FIT ALL 1 PRIMARY IMMUNODEFICIENCIES ABBREVIATIONS IG IPOPI IV PID SC Immunoglobulins
More informationDEBRIDEMENT: ANATOMY and PHYSIOLOGY. Professor Donald G. MacLellan Executive Director Health Education & Management Innovations
DEBRIDEMENT: ANATOMY and PHYSIOLOGY Professor Donald G. MacLellan Executive Director Health Education & Management Innovations ANATOMY and PHYSIOLOGY Epidermal Layers ECM Structure Dermis Structure Skin
More informationCell Walls, the Extracellular Matrix, and Cell Interactions (part 1)
14 Cell Walls, the Extracellular Matrix, and Cell Interactions (part 1) Introduction Many cells are embedded in an extracellular matrix which is consist of insoluble secreted macromolecules. Cells of bacteria,
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationRoche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma
Media Release Basel, 12 January 2017 Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma Administration time significantly reduced
More informationSynopsis (C0524T12 GO LIVE)
Protocol: EudraCT No.: 2005-003232-21 Title of the study: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Intravenously,
More informationCRYSTALOMICS FORMULATION TECHNOLOGY
CRYSTALOMICS FORMULATION TECHNOLOGY INTRODUCTION Over the past decade, protein-based therapeutics have emerged as a key driver of growth in the pharmaceutical industry. R&D pipelines have filled with biologics
More informationConnective Tissue (CT)
Connective Tissue (CT) YONG-MEI CHEN ( 陈咏梅 ) Dept. of Anatomy, Histology & Embryology Peking Union Medical College Tel:69156461 E-mail address: pumc_he@126.com Content Introduction of CT 1. Origin 2. Compositions
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationPolicy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015
Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationIg Therapy: One Size Does Not Fit All
Ig Therapy: One Size Does Not Fit All Carla Duff, CPNP, MSN, IgCN Advanced Registered Nurse Practitioner University of South Florida Division of Allergy, Immunology, and Rheumatology 1 Objectives Understand
More informationMost mammalian cells are located in tissues where they are surrounded by a complex extracellular matrix (ECM) often referred to as connective tissue.
GLYCOSAMINOGLYCANS Most mammalian cells are located in tissues where they are surrounded by a complex extracellular matrix (ECM) often referred to as connective tissue. The ECM contains three major classes
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 21 days Regimen *Reimbursement INDICATION ICD10 Code Status HER2 positive metastatic breast cancer (MBC) C50 00200a Hospital HER2 positive early breast
More informationTCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol
Systemic Anti Cancer Treatment Protocol TCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol PROTOCOL REF: MPHATCHP (Version No: 1.0) Approved for use in: Neoadjuvant breast: The neoadjuvant
More informationRituximab for subcutaneous delivery: Clinical management principles from a nursing perspective
bs_bs_banner International Journal of Nursing Practice 2015; 21 (Suppl. 2), 1 13 SUPPLEMENT ARTICLE Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective Julia
More informationNCCP Chemotherapy Regimen. DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days
DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Status Adjuvant treatment HER2 positive early breast cancer C50 00258a Hospital
More informationINTRATHECAL APPLICATION OF MONOCLONAL ANTIBODIES. Samo Rožman Institute of Oncology Ljubljana Slovenia
INTRATHECAL APPLICATION OF MONOCLONAL ANTIBODIES Samo Rožman Institute of Oncology Ljubljana Slovenia AGENDA 1. INTRATHECAL APPLICATION 2. MONOCLONAL ANTIBODIES 3. MALIGNANT CARCINOMATOSIS 4. INTRATHECAL
More informationHyaluronan Quantification Kit
Product manual (ELISA-like assay for HA / Hyaluronic Acid) Updated on Jan. 6th, 207 - Background Hyaluronan (HA) is an unbranched glycosaminoglycan composed of repeating disaccharide units of D-glucronic
More informationSponsor: Sanofi Drug substance(s): SAR342434
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationPharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study Andrew Davies, Francesco Merli, Biljana Mihaljevic, Noppadol Siritanaratkul,
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationCAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections
CAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections Dr. Fredrik Tiberg Assoc. Prof. President & CEO, Head R&D, Camurus Lund,
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationHerceptin SC (Subcutaneous Trastuzumab)
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Rate 1 Herceptin SC (trastuzumab) 600mg S/C 2 to 5 mins *PRECAUTION: In order to reduce the risk of medication errors it is recommended that all trastuzumab
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationPharmacokinetic parameters: Halflife
Pharmacokinetic parameters: Halflife (t 1/2 ) 1. By definition t 1/2 is the time required for the concentration to fall by one half. For drugs with first order kinetics this is a constant. 2. Half-life
More informationRoche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer
Media Release Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationIl ruolo degli anticorpi anti farmaco nella pratica clinica
Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring
More informationPharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia
British Journal of Clinical Pharmacology DOI:10.1111/bcp.12662 Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia
More informationGlycosaminoglycans, Proteoglycans, and Glycoproteins
Glycosaminoglycans, Proteoglycans, and Glycoproteins Presented by Dr. Mohammad Saadeh The requirements for the Pharmaceutical Biochemistry I Philadelphia University Faculty of pharmacy I. OVERVIEW OF GLYCOSAMINOGLYCANS
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationAn aldose contains an aldehyde functionality A ketose contains a ketone functionality
RCT Chapter 7 Aldoses and Ketoses; Representative monosaccharides. (a)two trioses, an aldose and a ketose. The carbonyl group in each is shaded. An aldose contains an aldehyde functionality A ketose contains
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationInvestor Update. Downloads. Services PDF. Basel, 23 June 2017
Investor Update Basel, 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes,
More informationPharmacology Updates in Breast Cancer Chris Vaklavas, M.D.
Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D. Assistant Professor Department of Medicine, Division of Hematology/Oncology University of Alabama at Birmingham NP2540M 1802 6th Avenue South
More informationXiaoping (Amy) Zhang, Varun Goel, Husain Attarwala, and Gabriel Robbie. Alnylam Pharmaceuticals, Cambridge, USA
Patisiran Pharmacokinetics (PK), Pharmacodynamics (PD), and Exposure-Response (E-R) Relationship in Patients with Hereditary Transthyretin-Mediated (hattr) Amyloidosis Xiaoping (Amy) Zhang, Varun Goel,
More informationSubcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency
Subcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency EDUCATIONAL OBJECTIVES Upon completion of this program, participants should be better able to: 1.
More informationPRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients
PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Pertuzumab (Perjeta) Neoadjuvant Breast Cancer July 16, 2015
pan-canadian Oncology Drug Review Final Economic Guidance Report Pertuzumab (Perjeta) Neoadjuvant Breast Cancer July 16, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationNovel Formulations to Modify Mealtime Insulin Kinetics
Novel Formulations to Modify Mealtime Insulin Kinetics Alan Krasner, Roderike Pohl, Patrick Simms, Philip Pichotta, Robert Hauser, Errol De Souza Biodel, Inc. Danbury, CT Disclosure All authors are employees
More informationVol. 38 No. 5 November 2009 Journal of Pain and Symptom Management 663
Vol. 38 No. 5 November 29 Journal of Pain and Symptom Management 663 Original Article The INFUSE-Morphine Study: Use of Recombinant Human Hyaluronidase (rhuph2) to Enhance the Absorption of Subcutaneously
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationAssay Kit for Measurement of Proteoglycan. (Sulfated Glycosaminoglycan Quantification Kit)
Assay Kit for Measurement of Proteoglycan. (Sulfated Glycosaminoglycan Quantification Kit) Cat. No. 280560-N INTRODUCTION Glycosaminoglycans (GAGs) are a major component of the extracellular matrix (ECM)
More informationSingle Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody, in Heavily Pretreated HER2-Expressing Cancers
Single Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody, in Heavily Pretreated HER2-Expressing Cancers 1, Murali Beeram 2, Jose Mayordomo 3, Diana Hanna 4, Jaffer Ajani 1, Mariela Blum Murphy
More informationScottish Medicines Consortium
P Oral) Scottish Medicines Consortium vinorelbine 20 and 30mg capsules (NavelbineP Pierre Fabre Ltd No. (179/05) 06 May 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationSponsor/Company: sanofi-aventis Drug substance: Elitek/Fasturtec (rasburicase, SR29142)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: sanofi-aventis Drug
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationGlycosaminoglycans: Anionic polysaccharide chains made of repeating disaccharide units
Glycosaminoglycans: Anionic polysaccharide chains made of repeating disaccharide units Glycosaminoglycans present on the animal cell surface and in the extracellular matrix. Glycoseaminoglycans (mucopolysaccharides)
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 September 22.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1990 February ; 22(1): 57 59. Effect of Hepatic Dysfunction and T Tube Clamping on FK 506 Pharmacokinetics and Trough
More informationCurrent and Future perspectives of HER2+ BC
2018.4.6 GBCC Satellite symposium Current and Future perspectives of HER2+ BC Jee Hyun Kim, M.D., Ph.D. Seoul National University Bundang Hospital Seoul National University College of Medicine Disclaimer
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationOffice based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2
Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2 1 The Male Health Centre, Oakville, Ontario, Canada 2 Humber River Regional Hospital, University of Toronto, Toronto,
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Pembrolizumab 2mg/kg INDICATION ICD10 Regimen Code *Reimbursement Status First line monotherapy for the treatment of advanced (unresectable or C43 00347a ODMS metastatic) melanoma
More informationScottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationAT Hickerson 1, GT Clifton 1, DF Hale 1, KM Peace 1, JP Holmes 2, TJ Vreeland 3, JK Litton 4, RK Murthy 4, KK Lukas 5, EA Mittendorf 6, GE Peoples 7
Final analysis of Nelipepimut-S plus GM-CSF with trastuzumab versus GM-CSF with trastuzumab to prevent recurrences in high-risk, HER2 low-expressing breast cancer: a prospective, randomized, blinded multicenter
More informationPRACTICAL APPLICATION INSTYLAN MODERN PROTECTOR OF URINARY BLADDER MUCOSA
PRACTICAL APPLICATION INSTYLAN MODERN PROTECTOR OF URINARY BLADDER MUCOSA E.O. Stakhovsky, PhD, MD, Professor, Head of the Scientific and Research Department of Plastic and Reconstructive Oncourology,
More informationComparison of nasogastric and intravenous methods of rehydration in pediatric patients with acute dehydration Nager A L, Wang V J
Comparison of nasogastric and intravenous methods of rehydration in pediatric patients with acute dehydration Nager A L, Wang V J Record Status This is a critical abstract of an economic evaluation that
More informationA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release Oxycodone/Acetaminophen Tablets (CR OC/APAP) in an Acute Pain Model Neil
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationRoche s Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer
Media Release Basel, 31 July, 2015 Roche s Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer The approval is based on the benefit seen with the Perjeta regimen
More informationHerceptin IV (Trastuzumab) and Paclitaxel Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Given as a three weekly schedule Day Drug Daily Dose Route Diluent & Rate On first cycle 250mls Normal Saline Herceptin IV 8 mg/kg Infusion only 90 mins On other 250mls Normal
More informationNext Generation Therapeutics for Disorders of Complement Regulation
Next Generation Therapeutics for Disorders of Complement Regulation March 2018 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities
More informationFEC-T plus trastuzumab & pertuzumab
Page 1 of 5 Indication Treatment Intent Frequency and number of cycles Monitoring parameters pre-treatment The neoadjuvant treatment of locally advanced, inflammatory or early HER2 positive breast cancer
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationFactors impacting the SC bioavailability of therapeutic antibodies
Factors impacting the SC bioavailability of therapeutic antibodies How can we improve it? Saileta Prabhu 19 May 2014 SC bioavailability (%) of therapeutic antibodies in humans varies to a large extent
More informationCurrent situation and future of renal anemia treatment. FRANCESCO LOCATELLI
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationMedia Release. Basel, 26 March 2018
Media Release Basel, 26 March 2018 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live
More informationTransCon CNP: Preliminary Phase 1 Data. November 28, 2018
TransCon CNP: Preliminary Phase Data November 28, 28 Normal Growth Depends on Balanced Pathways CNP Activity FGFR3 Activity FGFR3 CNP FGFR3 CNP Normal growth Achondroplasia growth TransCon CNP is designed
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More information4. Aflibercept showed significant improvement in overall survival (OS), the primary
Cost effectiveness of aflibercept (Zaltrap ) in combination with FOLFIRI in the treatment of adult patients with metastatic colorectal cancer (mcrc) that is resistant to or has progressed after an oxaliplatin
More informationName of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb ligand
Page 2 of 1765 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More information2
1 2 Systematic review of published evidence PUBMED 1999-2017 ASCO 1999-2017 SABCS 1999-2017 ECCO/ESMO 1999-2017 3 Statement: Anthracycline/ taxane based chemotherapy 1. Budd GT et al. SWOG S0221: A Phase
More informationPhase I and Pharmacodynamic Study of High-Dose NGR-hTNF in Patients
Phase I and Pharmacodynamic Study of High-Dose NGR-hTNF in Patients with Refractory Solid Tumors P. A. Zucali 1, A. Santoro 1, M. Simonelli 1, F. De Vincenzo 1, E. Lorenzi 1, L. Rimassa 1, L. Balzarini
More informationClinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children. January 2013 Reference: NHS England XXX/X/X.
Clinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children January 2013 Reference: NHS England XXX/X/X England 1 NHS England Clinical Commissioning Policy: Chemotherapy Algorithms for
More informationClinical Trial List
Clinical Trial List 2005 2008 Service Driven. Quality Focused. Global Perspective. Clinical Trial List 2005-2008 1 Pharmacokinetic A Two-Period, Single Dose Pharmacokinetic Study of Three Sustained-Release
More informationPROMISE 2 Top-Line Data Results January 8, 2018
PROMISE 2 Top-Line Data Results January 8, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationEssais de supériorité / d équivalence / de non-infériorité. Prof. X Pivot
Essais de supériorité / d équivalence / de non-infériorité Prof. X Pivot Confidence interval 95% Superiority P=0,002 P=0,05 HR 0,75 (95%CI: 0,90 0,50) HR 0,80 (95%CI: 1 0,65) 1 Ratio of events over the
More informationAll Studies by Indication
Therapeutic Area Protocol Number Drug/Device Phase Description Advanced malignancies 337 20101132 AMG 337 I " A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of
More informationPharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen
Pharmacokinetics in the critically ill Intensive Care Training Program Radboud University Medical Centre Nijmegen In general... Critically ill patients are at higher risk for ADE s and more severe ADE
More informationBC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab
BC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab Protocol Code Tumour Group Contact Physicians LYCLLFLUDR Lymphoma Dr.
More informationInfographic (right): ESMO 2014 record breaking Congress
ESMO 2014 Congress Scientific Meeting Report Supportive and Palliative Care Extract 26-30 September 2014 Madrid, Spain Summary The European Society for Medical Oncology (ESMO) Congress, held September
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationModeling and Simulation to Support Development and Approval of Complex Products
Modeling and Simulation to Support Development and Approval of Complex Products Mathangi Gopalakrishnan, MS, PhD Research Assistant Professor Center for Translational Medicine, School of Pharmacy, UMB
More information